ASH 2020 Meeting Highlights in Multiple Myeloma
Release Date: March 10, 2021
Expiration Date: March 10, 2022
Expected time to complete this activity as designed: 60 minutes
There are no fees for participating in or receiving credit for this online activity.
In this activity, experts will discuss a selection of key abstracts from the 2020 ASH Annual Meeting and describe how this data can be applied to clinical practice. Topics will include an update analysis of the GRIFFIN trial, review of BiTE therapy including the first-in-human study of talquetamab, CAR T-cell therapy, updated real-world results from the community-based US MM-6 study looking at iCT from parenteral bortezomib to oral ixazomib PI therapy, and the long-term follow-up analysis of the IFM 2009 trial looking at early versus late ASCT in newly diagnosed myeloma.
This activity is designed for multidisciplinary healthcare providers in the community setting, including physicians, nurses, pharmacists and other allied healthcare professionals who provide care to patients with multiple myeloma.
Upon completion of this educational activity, participants should be able to:
- Summarize clinical data supporting advances in novel treatment approaches and best practices for use of available treatments
- Demonstrate the ability to evaluate, integrate, and apply appropriate information from various sources of clinical data as it relates to emerging treatments and practice standards in MM
- ASH 2020 Meeting Highlights in Multiple Myeloma – Joshua Richter, MD
- ASH 2020 Meeting Highlights in Multiple Myeloma – Nina Shah, MD
- ASH 2020 Meeting Highlights in Multiple Myeloma – Adam D. Cohen, MD
Instructions for Participation and Credit
This activity is eligible for credit through March 10, 2022. After this date, this activity will expire and no further credit will be awarded.
- Read the target audience, learning objectives, and faculty disclosures.
- You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
- Complete the educational content as designed.
- Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
- Complete the activity evaluation survey to provide feedback and information useful for future programming.
- Certificates for CME and CNE may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.
Joshua Richter, MD
Assistant Professor of Medicine
Tisch Cancer Institute
Icahn School of Medicine at Mount Sinai
Director of Myeloma
Blavatnik Family Center at Chelsea Mount Sinai
New York, New York
Dr. Joshua Richter received his medical degree from New York Medical College. He completed an internal medicine residency at St. Vincent’s Hospital – New York Medical College, and a hematology/oncology fellowship at Yale Cancer Center, Yale University. Dr. Richter served as Clinical Assistant Professor at Rutgers University, New Brunswick, New Jersey, and worked in the Division of Myeloma at the John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey. He is currently an Assistant Professor of Medicine at the Icahn School of Medicine at Mount Sinai and Director of Myeloma at Blavatnik Family Center at Chelsea Mount Sinai.
Dr. Richter is board certified in internal medicine, hematology, and medical oncology. He has been published in numerous oncology journals including New England Journal of Medicine, Blood, Journal of Clinical Oncology, and the British Journal of Haematology. Dr. Richter specializes in multiple myeloma as well as other plasma cell dyscrasias such as amyloidosis and Waldenstrom’s macroglobulinemia. His clinical research interests focus on multi-functional antibodies and precision medicine.
Adam D. Cohen, MD
Director of Myeloma Immunotherapy
Associate Professor of Medicine
Abramson Cancer Center of the University of Pennsylvania
Dr. Adam Cohen received his medical degree and internal medicine training from the University of Pennsylvania in Philadelphia, and completed his hematology/medical oncology fellowship at Memorial Sloan-Kettering Cancer Center in New York City. He is currently Director of Myeloma Immunotherapy and an Associate Professor of Medicine at the Abramson Cancer Center of the University of Pennsylvania in Philadelphia.
Dr. Cohen is board certified in internal medicine, medical oncology, and hematology. He is a member of the American Society of Hematology (ASH), American Society of Clinical Oncology (ASCO), American Association for Cancer Research (AACR), and the International Myeloma Society, as well as a reviewer for a number of peer-reviewed journals. He has written dozens of original articles, book chapters, and reviews on cancer immunotherapy, multiple myeloma, amyloidosis, and stem cell transplant.
Nina Shah, MD
University of California San Francisco
San Francisco, California
Dr. Nina Shah is an Associate Professor in the Division of Hematology-Oncology at University of California San Francisco. Her research focuses on multiple myeloma, specifically immunotherapy and cellular therapy. Dr. Shah performed the first-in-human clinical trial of umbilical cord blood-derived natural killer cell therapy for myeloma and is currently one of the three lead principal investigators (PI) for the multi-center BMT CTN 1401 dendritic cell vaccine trial for myeloma patients. In addition, she is involved in numerous CAR-T and immunotherapy protocols.
Dr. Shah is also interested in outcomes research for myeloma patients undergoing autologous transplantation, she has led a randomized trial to determine the impact of stem cell dose on symptoms in this patient population and has also published on patient reported outcomes in this clinical context. Dr. Shah is heavily involved in the myeloma research community and led the effort to define myeloma-transplant practice guidelines for the American Society of Blood and Marrow Transplant (ASBMT). She serves as a co-chair for the Plasma Cell Disorders and Adult Solid Tumors Working Committee at the Center for International Blood & Marrow Transplant Research (CIBMTR).
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 1.0 contact hour of Continuing Education Credit. Universal Activity Number: 827-0000-21-009-H01-P. Knowledge-based CPE activity.
In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.
International Pharmacy Preceptors and Canadian Pharmacists: If you are in need of e-Profile ID to participate in an ACPE approved activity, please contact NABP customer service for further assistance as special handling is necessary. NABP customer service can be reached at (847) 391-4406.
Accreditation Statement: MediCom Worldwide, Inc., 101 Washington Street, Morrisville, PA 19067 is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.0 contact hour. Program Number: 21-009-136
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.
Dr. Joshua Richter has received honoraria related to formal advisory activities from Adaptive Biotechnologies, Celgene Corporation – A Bristol-Myers Squibb Company, Janssen Pharmaceuticals, Inc., Karyopharm Therapeutics, Secura Bio™, Inc., and Takeda Oncology; speakers’ bureau activities from Adaptive Biotechnologies, Celgene Corporation – A Bristol-Myers Squibb Company, Janssen, and Secura Bio, Inc.; as well as consultant fees from Karyopharm and Secura Bio.
Dr. Adam Cohen has received honoraria related to formal advisory activities from AstraZeneca, Bristol-Myers Squibb Company, Genentech – A Member of the Roche Group, GlaxoSmithKline plc, Janssen Pharmaceuticals, Inc., Oncopeptides, AB, and Takeda Oncology, as well as consultant fees from Bristol-Myers Squibb and Janssen . He has received grant support related to research activities from Bristol-Myers Squibb, Genentech – A Member of the Roche Group, GlaxoSmithKline, Janssen, and Novartis AG. He has also received royalties or licensing fees from Novartis.
Dr. Nina Shah has received honoraria as a consultant from Amgen Inc., CareDx, GlaxoSmithKline plc, Indapta Therapeutics, Karyopharm Therapeutics, Kite Pharma, Oncopeptides, AB, and Sanofi. She has received grant support related to research activities from bluebird bio, Inc., Celgene Corporation – A Bristol-Myers Squibb Company, Janssen Pharmaceuticals, Inc., Nektar, Poseida Therapeutics, Inc., Sutro Biopharma, and TeneoBio.
Planning Committee Disclosures
The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, Executive Director, Isabelle Vacher, Vice President of Educational Strategy, Wilma Guerra, Program Director, and Andrea Mathis, Project Manager, have no relevant financial relationships.
Peer Reviewer Disclosure
In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.
If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at [email protected]
Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC and Takeda Oncology.
©2021 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.